NASDAQ:MDSO - Medidata Solutions Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$82.39 -1.29 (-1.54 %)
(As of 06/24/2018 05:11 AM ET)
Previous Close$82.39
Today's Range$81.96 - $84.49
52-Week Range$59.60 - $85.92
Volume854,979 shs
Average Volume484,788 shs
Market Capitalization$4.96 billion
P/E Ratio96.93
Dividend YieldN/A
Medidata Solutions logoMedidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management. It also provides professional services, such as implementation, sponsor enablement, strategic consulting, partner and ongoing support, and e-learning and training. The company markets and sells its cloud-based solutions through a direct sales force, as well as through relationships with contract research organizations (CROs) and other strategic partners. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; academic research centers, government, and other non-profit organizations; and CROs and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.

Receive MDSO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Prepackaged software
Sub-IndustryHealth Care Technology


Debt-to-Equity Ratio0.18
Current Ratio1.63
Quick Ratio1.63


Trailing P/E Ratio96.93
Forward P/E Ratio108.41
P/E Growth5.37

Sales & Book Value

Annual Sales$545.53 million
Price / Sales8.94
Cash Flow$1.5291 per share
Price / Cash53.88
Book Value$8.51 per share
Price / Book9.68


EPS (Most Recent Fiscal Year)$0.85
Net Income$44.38 million
Net Margins7.96%
Return on Equity11.36%
Return on Assets5.59%


Outstanding Shares59,220,000

The Truth About Cryptocurrencies

Medidata Solutions (NASDAQ:MDSO) Frequently Asked Questions

What is Medidata Solutions' stock symbol?

Medidata Solutions trades on the NASDAQ under the ticker symbol "MDSO."

How were Medidata Solutions' earnings last quarter?

Medidata Solutions Inc (NASDAQ:MDSO) posted its quarterly earnings results on Thursday, April, 19th. The company reported $0.40 EPS for the quarter, beating the Zacks' consensus estimate of $0.35 by $0.05. The firm had revenue of $149.20 million for the quarter, compared to analysts' expectations of $146.73 million. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. The business's revenue for the quarter was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.31 earnings per share. View Medidata Solutions' Earnings History.

When is Medidata Solutions' next earnings date?

Medidata Solutions is scheduled to release their next quarterly earnings announcement on Monday, July, 16th 2018. View Earnings Estimates for Medidata Solutions.

What price target have analysts set for MDSO?

14 equities research analysts have issued 12 month price objectives for Medidata Solutions' stock. Their forecasts range from $78.00 to $98.00. On average, they anticipate Medidata Solutions' stock price to reach $86.9286 in the next twelve months. View Analyst Ratings for Medidata Solutions.

Who are some of Medidata Solutions' key competitors?

Who are Medidata Solutions' key executives?

Medidata Solutions' management team includes the folowing people:
  • Mr. Tarek A. Sherif, Co-Founder, Chairman and Chief Exec. Officer (Age 56)
  • Mr. Glen M. De Vries, Co-Founder, Pres & Director (Age 46)
  • Dr. Rouven Bergmann, CFO & Chief Accounting Officer (Age 45)
  • Mr. Michael I. Otner, Exec. VP, Gen. Counsel & Sec. (Age 47)
  • Ms. Julie Iskow, Exec. VP of Product Devel. & CTO

Has Medidata Solutions been receiving favorable news coverage?

News coverage about MDSO stock has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medidata Solutions earned a daily sentiment score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 45.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Medidata Solutions' major shareholders?

Medidata Solutions' stock is owned by many different of institutional and retail investors. Top institutional investors include Champlain Investment Partners LLC (3.63%), American Century Companies Inc. (2.44%), Global Thematic Partners LLC (2.34%), Disciplined Growth Investors Inc. MN (1.57%), Eagle Asset Management Inc. (1.49%) and Stephens Investment Management Group LLC (1.40%). Company insiders that own Medidata Solutions stock include Carlos Dominguez, Eileen Schloss, Michael I Otner, Michael L Capone, Michael Pray, Robert Taylor, Rouven Bergmann, Steven Isaac Hirschfeld, Tarek Sherif and Vries Glen Michael De. View Institutional Ownership Trends for Medidata Solutions.

Which institutional investors are selling Medidata Solutions stock?

MDSO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Russell Investments Group Ltd., Global Thematic Partners LLC, Carillon Tower Advisers Inc., PNC Financial Services Group Inc., Millennium Management LLC, Stevens Capital Management LP and Loomis Sayles & Co. L P. Company insiders that have sold Medidata Solutions company stock in the last year include Carlos Dominguez, Michael I Otner, Michael L Capone, Michael Pray, Robert Taylor, Rouven Bergmann and Tarek Sherif. View Insider Buying and Selling for Medidata Solutions.

Which institutional investors are buying Medidata Solutions stock?

MDSO stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Echo Street Capital Management LLC, Rockefeller Capital Management L.P., Champlain Investment Partners LLC, Massachusetts Financial Services Co. MA, Zevenbergen Capital Investments LLC, Disciplined Growth Investors Inc. MN and Eaton Vance Management. View Insider Buying and Selling for Medidata Solutions.

How do I buy shares of Medidata Solutions?

Shares of MDSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medidata Solutions' stock price today?

One share of MDSO stock can currently be purchased for approximately $82.39.

How big of a company is Medidata Solutions?

Medidata Solutions has a market capitalization of $4.96 billion and generates $545.53 million in revenue each year. The company earns $44.38 million in net income (profit) each year or $0.85 on an earnings per share basis. Medidata Solutions employs 1,680 workers across the globe.

How can I contact Medidata Solutions?

Medidata Solutions' mailing address is 350 HUDSON ST. 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 212-918-1800 or via email at [email protected]

MarketBeat Community Rating for Medidata Solutions (MDSO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Medidata Solutions and other stocks. Vote "Outperform" if you believe MDSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.